Tags

Type your tag names separated by a space and hit enter

Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndrome.
Int J Colorectal Dis. 2020 Jan; 35(1):139-145.IJ

Abstract

BACKGROUND

The symptoms of irritable bowel syndrome (IBS) lead to considerable impairment of health-related quality of life and high health care costs. Available therapies are not efficient in treating the symptoms of IBS. Studies have shown the beneficial effects of Saccharomyces cerevisiae CNCM I-3856. Therefore, this study was done to evaluate the efficacy and safety of S. cerevisiae CNCM I-3856 in the treatment of IBS.

METHODS

This was a prospective, randomized, placebo-controlled study. One hundred newly diagnosed subjects with IBS were subgrouped into IBS-D, IBS-C, and IBS-M and then randomized to the S. cerevisiae CNCM I-3856 and placebo groups. Saccharomyces cerevisiae/placebo was administered in addition to standard treatment for a period of 8 weeks. Subjects were assessed for improvement of abdominal pain and change in stool consistency using a 7-point Likert scale and Bristol stool scale respectively.

RESULTS

The mean reduction of abdominal pain score in the S. cerevisiae CNCM I-3856 group was statistically significant when compared with the placebo group (p < 0.001). Similar improvement was also seen in the subgroups. Improvement in stool consistency in IBS-D subgroup at the end of treatment period was found to be statistically significant in S. cerevisiae group when compared to that of placebo (p < 0.001). A similar improvement was seen in the IBS-C and IBS-M subgroups. No serious adverse events were recorded in both groups.

CONCLUSION

The use of Saccharomyces cerevisiae CNCM I-3856 in IBS at a dose of 2 billion CFU twice daily for 8 weeks has shown to have an improvement in abdominal pain and stool consistency due to its analgesic and anti-inflammatory activity in subjects with IBS.

Authors+Show Affiliations

Department of Pharmacology, Kilpauk Medical College, Chennai, Tamil Nadu, India.Department of Pharmacology, Kilpauk Medical College, Chennai, Tamil Nadu, India.Department of Pharmacology, Kilpauk Medical College, Chennai, Tamil Nadu, India.Department of Medical & Scientific Affairs, Tablets India Limited, Jhaver Centre, 72 Marshalls Road, Egmore, Chennai, 600008, India.Department of Medical & Scientific Affairs, Tablets India Limited, Jhaver Centre, 72 Marshalls Road, Egmore, Chennai, 600008, India. ds@tabletsindia.com.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

31807856

Citation

Gayathri, Ravichandran, et al. "Efficacy of Saccharomyces Cerevisiae CNCM I-3856 as an Add-on Therapy for Irritable Bowel Syndrome." International Journal of Colorectal Disease, vol. 35, no. 1, 2020, pp. 139-145.
Gayathri R, Aruna T, Malar S, et al. Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndrome. Int J Colorectal Dis. 2020;35(1):139-145.
Gayathri, R., Aruna, T., Malar, S., Shilpa, B., & Dhanasekar, K. R. (2020). Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndrome. International Journal of Colorectal Disease, 35(1), 139-145. https://doi.org/10.1007/s00384-019-03462-4
Gayathri R, et al. Efficacy of Saccharomyces Cerevisiae CNCM I-3856 as an Add-on Therapy for Irritable Bowel Syndrome. Int J Colorectal Dis. 2020;35(1):139-145. PubMed PMID: 31807856.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndrome. AU - Gayathri,Ravichandran, AU - Aruna,Thangavelu, AU - Malar,Sivaraman, AU - Shilpa,Bennur, AU - Dhanasekar,Karukkupalayam Ramasamy, Y1 - 2019/12/05/ PY - 2019/11/14/accepted PY - 2019/12/7/pubmed PY - 2020/10/2/medline PY - 2019/12/7/entrez KW - Bristol stool scale KW - Functional GI disorders KW - Likert scale KW - Probiotics KW - Rome III criteria SP - 139 EP - 145 JF - International journal of colorectal disease JO - Int J Colorectal Dis VL - 35 IS - 1 N2 - BACKGROUND: The symptoms of irritable bowel syndrome (IBS) lead to considerable impairment of health-related quality of life and high health care costs. Available therapies are not efficient in treating the symptoms of IBS. Studies have shown the beneficial effects of Saccharomyces cerevisiae CNCM I-3856. Therefore, this study was done to evaluate the efficacy and safety of S. cerevisiae CNCM I-3856 in the treatment of IBS. METHODS: This was a prospective, randomized, placebo-controlled study. One hundred newly diagnosed subjects with IBS were subgrouped into IBS-D, IBS-C, and IBS-M and then randomized to the S. cerevisiae CNCM I-3856 and placebo groups. Saccharomyces cerevisiae/placebo was administered in addition to standard treatment for a period of 8 weeks. Subjects were assessed for improvement of abdominal pain and change in stool consistency using a 7-point Likert scale and Bristol stool scale respectively. RESULTS: The mean reduction of abdominal pain score in the S. cerevisiae CNCM I-3856 group was statistically significant when compared with the placebo group (p < 0.001). Similar improvement was also seen in the subgroups. Improvement in stool consistency in IBS-D subgroup at the end of treatment period was found to be statistically significant in S. cerevisiae group when compared to that of placebo (p < 0.001). A similar improvement was seen in the IBS-C and IBS-M subgroups. No serious adverse events were recorded in both groups. CONCLUSION: The use of Saccharomyces cerevisiae CNCM I-3856 in IBS at a dose of 2 billion CFU twice daily for 8 weeks has shown to have an improvement in abdominal pain and stool consistency due to its analgesic and anti-inflammatory activity in subjects with IBS. SN - 1432-1262 UR - https://www.unboundmedicine.com/medline/citation/31807856/Efficacy_of_Saccharomyces_cerevisiae_CNCM_I_3856_as_an_add_on_therapy_for_irritable_bowel_syndrome_ L2 - https://doi.org/10.1007/s00384-019-03462-4 DB - PRIME DP - Unbound Medicine ER -